RxSight, Inc. (RXST)

NASDAQ: RXST · IEX Real-Time Price · USD
14.25
+1.06 (8.04%)
At close: Jan 27, 2023, 4:00 PM
14.96
+0.71 (4.98%)
After-hours: Jan 27, 2023, 7:11 PM EST

Stock Price Forecast

According to 11 stock analysts, the average 12-month stock price forecast for RxSight stock is $19.79, which predicts an increase of 38.88%. The lowest target is $14.14 and the highest is $25.2. On average, analysts rate RxSight stock as a buy.
Analyst Consensus: Buy
Target Low Average Median High
Price $14.14 $19.79 $22.44 $25.2
Change -0.77% +38.88% +57.47% +76.84%

Analyst Ratings

The average analyst rating for RxSight stock from 11 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating Aug '22Sep '22Oct '22Nov '22Dec '22Jan '23
Strong Buy 333444
Buy 666665
Hold 111112
Sell 000000
Strong Sell 000000
Total 101010111111

Financial Forecast

Revenue This Year
48.53M
from 22.59M
Increased by 114.78%
Revenue Next Year
81.58M
from 48.53M
Increased by 68.12%
EPS This Year
-2.60
from -3.57
EPS Next Year
-2.25
from -2.60
Year 20192020202120222023202420252026
Revenue
2.24M14.68M22.59M48.53M81.58M111.59M147.24M171.46M
Revenue Growth
-
554.98%
53.92%
114.78%
68.12%
36.79%
31.95%
16.45%
EPS
-0.15-3.57-2.60-2.25-1.72-1.04-0.72
EPS Growth
--------
No. Analysts ---77633

Revenue Forecast

Revenue 20222023202420252026
High 50.4M 92.9M 123.2M 156.7M 176.5M
Avg 48.5M 81.6M 111.6M 147.2M 171.5M
Low 46.5M 73.5M 98.0M 136.7M 164.7M

Revenue Growth

Revenue Growth 20222023202420252026
High
123.1%
91.5%
51.0%
40.4%
19.9%
Avg
114.8%
68.1%
36.8%
31.9%
16.4%
Low
105.6%
51.5%
20.1%
22.5%
11.9%

EPS Forecast

EPS 20222023202420252026
High -2.66 -1.97 -1.25 -1.07 -0.75
Avg -2.60 -2.25 -1.72 -1.04 -0.72
Low -2.54 -2.61 -2.43 -1.00 -0.70

EPS Growth

EPS Growth 20222023202420252026
High - - - - -
Avg - - - - -
Low - - - - -
Sources: Price target, rating and forecast data provided by Finnhub and sourced from Wall Street analysts and other sell-side and buy-side analysts and investors. Data disclaimer.